SGLT-2 inhibitor market seen topping $11 billion by 2030

By AI, Created 1:12 PM UTC, June 04, 2026, /AGP/ – The market for empagliflozin, dapagliflozin and canagliflozin is projected to rise from $9.84 billion in 2025 to $11.08 billion by 2030, driven by growing type 2 diabetes cases and broader use in heart failure and kidney protection. North America led the market in 2025, according to The Business Research Company.

Why it matters: - Empagliflozin, dapagliflozin and canagliflozin are already moving beyond diabetes treatment into heart failure and renal protection, expanding the drugs’ commercial reach. - The market’s projected climb to $11.08 billion by 2030 signals continued demand for oral diabetes medicines as chronic disease rates rise. - The trend matters for drug makers, clinicians and payers because these medicines are increasingly tied to long-term diabetes, cardiovascular and kidney care.

What happened: - The Business Research Company released its 2026 market report on the global empagliflozin, dapagliflozin and canagliflozin market on June 4, 2026. - The report values the market at $9.84 billion in 2025 and forecasts $10.07 billion in 2026. - The same report projects the market will reach $11.08 billion by 2030, implying a 2.4% compound annual growth rate across the forecast period. - North America was the largest regional market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Empagliflozin, dapagliflozin and canagliflozin are sodium-glucose co-transporter-2, or SGLT-2, inhibitors. - The drugs are oral medications primarily used to manage type 2 diabetes mellitus. - The medicines are often used with diet, exercise and other diabetes treatments to control blood sugar. - The report links recent market growth to rising type 2 diabetes prevalence, wider acceptance of oral diabetes drugs, updates to clinical guidelines, greater awareness of cardiovascular risk and more lifestyle-related disease. - The forecast period is supported by broader use in heart failure, growing evidence of kidney protection, increased combination therapy use, an aging global population and stronger chronic disease management. - Emerging trends include expanded SGLT-2 use in type 2 diabetes, more cardiovascular benefit indications, rising preference for oral antidiabetic drugs, growth in combination therapies and emphasis on long-term blood sugar control. - The report also highlights new 2026 additions, including market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and future trend analysis.

Between the lines: - The market is no longer defined only by glucose control. - Clinical evidence and guideline changes are pushing SGLT-2 drugs into broader cardiometabolic care, which can support demand even in a slower-growth category. - The reported 2.4% CAGR suggests steady expansion rather than a breakout growth cycle.

What’s next: - The market’s next phase will likely depend on how quickly heart failure and kidney-protection use cases translate into routine prescribing. - Combination therapies and broader chronic disease management could help sustain demand through 2030. - The Business Research Company is also promoting related 2026 reports in transplant diagnostics, blood transfusion diagnostics and cancer diagnostics.